These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36427491)

  • 1. The miniature CRISPR-Cas12m effector binds DNA to block transcription.
    Wu WY; Mohanraju P; Liao C; Adiego-Pérez B; Creutzburg SCA; Makarova KS; Keessen K; Lindeboom TA; Khan TS; Prinsen S; Joosten R; Yan WX; Migur A; Laffeber C; Scott DA; Lebbink JHG; Koonin EV; Beisel CL; van der Oost J
    Mol Cell; 2022 Dec; 82(23):4487-4502.e7. PubMed ID: 36427491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CRISPR-associated DNA-cleaving enzyme Cpf1 also processes precursor CRISPR RNA.
    Fonfara I; Richter H; Bratovič M; Le Rhun A; Charpentier E
    Nature; 2016 Apr; 532(7600):517-21. PubMed ID: 27096362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural Basis for the Canonical and Non-canonical PAM Recognition by CRISPR-Cpf1.
    Yamano T; Zetsche B; Ishitani R; Zhang F; Nishimasu H; Nureki O
    Mol Cell; 2017 Aug; 67(4):633-645.e3. PubMed ID: 28781234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Innate programmable DNA binding by CRISPR-Cas12m effectors enable efficient base editing.
    Bigelyte G; Duchovska B; Zedaveinyte R; Sasnauskas G; Sinkunas T; Dalgediene I; Tamulaitiene G; Silanskas A; Kazlauskas D; Valančauskas L; Madariaga-Marcos J; Seidel R; Siksnys V; Karvelis T
    Nucleic Acids Res; 2024 Apr; 52(6):3234-3248. PubMed ID: 38261981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure of the type V-C CRISPR-Cas effector enzyme.
    Kurihara N; Nakagawa R; Hirano H; Okazaki S; Tomita A; Kobayashi K; Kusakizako T; Nishizawa T; Yamashita K; Scott DA; Nishimasu H; Nureki O
    Mol Cell; 2022 May; 82(10):1865-1877.e4. PubMed ID: 35366394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimized protocols for the characterization of Cas12a activities.
    Martin L; Rostami S; Rajan R
    Methods Enzymol; 2023; 679():97-129. PubMed ID: 36682874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural Variation of Type I-F CRISPR RNA Guided DNA Surveillance.
    Pausch P; Müller-Esparza H; Gleditzsch D; Altegoer F; Randau L; Bange G
    Mol Cell; 2017 Aug; 67(4):622-632.e4. PubMed ID: 28781236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure of the miniature type V-F CRISPR-Cas effector enzyme.
    Takeda SN; Nakagawa R; Okazaki S; Hirano H; Kobayashi K; Kusakizako T; Nishizawa T; Yamashita K; Nishimasu H; Nureki O
    Mol Cell; 2021 Feb; 81(3):558-570.e3. PubMed ID: 33333018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PAM recognition by miniature CRISPR-Cas12f nucleases triggers programmable double-stranded DNA target cleavage.
    Karvelis T; Bigelyte G; Young JK; Hou Z; Zedaveinyte R; Budre K; Paulraj S; Djukanovic V; Gasior S; Silanskas A; Venclovas Č; Siksnys V
    Nucleic Acids Res; 2020 May; 48(9):5016-5023. PubMed ID: 32246713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanistic Insights into the cis- and trans-Acting DNase Activities of Cas12a.
    Swarts DC; Jinek M
    Mol Cell; 2019 Feb; 73(3):589-600.e4. PubMed ID: 30639240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Miniature type V-F CRISPR-Cas nucleases enable targeted DNA modification in cells.
    Bigelyte G; Young JK; Karvelis T; Budre K; Zedaveinyte R; Djukanovic V; Van Ginkel E; Paulraj S; Gasior S; Jones S; Feigenbutz L; Clair GS; Barone P; Bohn J; Acharya A; Zastrow-Hayes G; Henkel-Heinecke S; Silanskas A; Seidel R; Siksnys V
    Nat Commun; 2021 Oct; 12(1):6191. PubMed ID: 34702830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural Basis for Guide RNA Processing and Seed-Dependent DNA Targeting by CRISPR-Cas12a.
    Swarts DC; van der Oost J; Jinek M
    Mol Cell; 2017 Apr; 66(2):221-233.e4. PubMed ID: 28431230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition Mechanism of an Anti-CRISPR Suppressor AcrIIA4 Targeting SpyCas9.
    Yang H; Patel DJ
    Mol Cell; 2017 Jul; 67(1):117-127.e5. PubMed ID: 28602637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmable RNA recognition and cleavage by CRISPR/Cas9.
    O'Connell MR; Oakes BL; Sternberg SH; East-Seletsky A; Kaplan M; Doudna JA
    Nature; 2014 Dec; 516(7530):263-6. PubMed ID: 25274302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural Basis for the Inhibition of CRISPR-Cas12a by Anti-CRISPR Proteins.
    Zhang H; Li Z; Daczkowski CM; Gabel C; Mesecar AD; Chang L
    Cell Host Microbe; 2019 Jun; 25(6):815-826.e4. PubMed ID: 31155345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA targeting by subtype I-D CRISPR-Cas shows type I and type III features.
    Lin J; Fuglsang A; Kjeldsen AL; Sun K; Bhoobalan-Chitty Y; Peng X
    Nucleic Acids Res; 2020 Oct; 48(18):10470-10478. PubMed ID: 32960267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assembly of Francisella novicida Cpf1 endonuclease in complex with guide RNA and target DNA.
    Alcón P; Montoya G; Stella S
    Acta Crystallogr F Struct Biol Commun; 2017 Jul; 73(Pt 7):409-415. PubMed ID: 28695850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mg
    Son H; Park J; Hwang I; Jung Y; Bae S; Lee S
    Proc Natl Acad Sci U S A; 2021 Dec; 118(49):. PubMed ID: 34853172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A detailed cell-free transcription-translation-based assay to decipher CRISPR protospacer-adjacent motifs.
    Maxwell CS; Jacobsen T; Marshall R; Noireaux V; Beisel CL
    Methods; 2018 Jul; 143():48-57. PubMed ID: 29486239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Target DNA recognition and cleavage by a reconstituted Type I-G CRISPR-Cas immune effector complex.
    Majumdar S; Ligon M; Skinner WC; Terns RM; Terns MP
    Extremophiles; 2017 Jan; 21(1):95-107. PubMed ID: 27582008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.